Integrated Filing — IndAS



General information about company
Scrip Code 539523
NSE Symbol ALKEM
MSEI Symbol NOTLISTED
ISIN INE540L01014
Name of company ALKEM LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 16-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment The Company is exclusively engaged in pharmaceutical business
Start date and time of board meeting 29-May-2025   11:25:00
End date and time of board meeting 29-May-2025   13:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-05-29
Indicate Company website link for updated RPT policy of the Company www.alkemlabs.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No defaults on loans and debt securities



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 20449400000 88134400000
Other income 1115900000 5070600000
Total income 21565300000 93205000000
2 Expenses
(a) Cost of materials consumed 4514100000 23959200000
(b) Purchases of stock-in-trade 852400000 3896100000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 1871400000 566100000
(d) Employee benefit expense 4016300000 16309600000
(e) Finance costs 169100000 761100000
(f) Depreciation, depletion and amortisation expense 916400000 2836100000
(f) Other Expenses
1 Other Expenses 6227300000 21841400000
Total other expenses 6227300000 21841400000
Total expenses 18567000000 70169600000
3 Total profit before exceptional items and tax 2998300000 23035400000
4 Exceptional items 0 0
5 Total profit before tax 2998300000 23035400000
6 Tax expense
7 Current tax 367500000 3501300000
8 Deferred tax 372000000 -1363100000
9 Total tax expenses 739500000 2138200000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 2258800000 20897200000
12 Profit (loss) from discontinued operations before tax 784800000 2938500000
13 Tax expense of discontinued operations 274200000 1026800000
14 Net profit (loss) from discontinued operation after tax 510600000 1911700000
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 2769400000 22808900000
17 Other comprehensive income net of taxes -40300000 -115000000
18 Total Comprehensive Income for the period 2729100000 22693900000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 239100000 239100000
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 122979200000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 18.89 174.78
Diluted earnings (loss) per share from continuing operations 18.89 174.78
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 4.28 15.99
Diluted earnings (loss) per share from discontinued operations 4.28 15.99
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 23.17 190.77
Diluted earnings (loss) per share from continuing and discontinued operations 23.17 190.77
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 14823700000
Capital work-in-progress 458200000
Investment property
Goodwill 0
Other intangible assets 1089700000
Intangible assets under development 306800000
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 37515400000
Trade receivables, non-current
Loans, non-current 90700000
Other non-current financial assets 2840400000
Total non-current financial assets 40446500000
Deferred tax assets (net) 14291400000
Other non-current assets 1059000000
Total non-current assets 72475300000
2 Current assets
Inventories 15229000000
Current financial asset
Current investments 6552400000
Trade receivables, current 15598400000
Cash and cash equivalents 749200000
Bank balance other than cash and cash equivalents 9811900000
Loans, current 16500000
Other current financial assets 19246100000
Total current financial assets 51974500000
Current tax assets (net) 0
Other current assets 6336500000
Total current assets 73540000000
3 Non-current assets classified as held for sale 9940700000
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 155956000000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 239100000
Other equity 122979200000
Total equity attributable to owners of parent 123218300000
Non controlling interest
Total equity 123218300000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 1290000000
Total non-current financial liabilities 1290000000
Provisions, non-current 2638900000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities 208500000
Total non-current liabilities 4137400000
Current liabilities
Current financial liabilities
Borrowings, current 3712400000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 651200000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 13986600000
Total Trade payable 14637800000
Other current financial liabilities 4057600000
Total current financial liabilities 22407800000
Other current liabilities 1285900000
Provisions, current 1356900000
Current tax liabilities (Net) 383800000
Deferred government grants, Current
Total current liabilities 25434400000
3 Liabilities directly associated with assets in disposal group classified as held for sale 3165900000
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 32737700000
Total equity and liabilites 155956000000
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block
Textual Information(1) 1. The above standalone financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI LODR Regulations 2015 as amended. n n2. The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 28 May 2025 and subsequently approved by the Board of Directors at its meeting held on 29 May 2025. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2025. n nThe figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevent financial year. n n3. The Board of Directors of the Company at their meeting held on 10 December 2024 have approved to transfer its Generic Business Undertaking to Alkem Wellness Limited a wholly owned subsidiary of the Company as a going concern on a slump sale basis. n nConsequently the proposed transfer of the Generic Business has been disclosed as discontinued operations in accordance with Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. The previous period have been restated to give effect to the presentation requirement of Ind AS 105. n nThe Company is currently in process of executing the Business Transfer Agreement which is expected to be completed on 01 October 2025. n n4. Key financial information of Discontinued Operations Amt in INR millions n nQuarter ended 31.03.2025 nTotal Revenue from Operations: 5190.5 nTotal expenses: 4405.7 nProfit before tax: 784.8 nTotal tax expense: 274.2 nNet profit for the period : 510.6 n nQuarter ended 31.12.2024 nTotal Revenue from Operations: 4880.4 nTotal expenses: 4159.7 nProfit before tax: 720.7 nTotal tax expense: 251.8 nNet profit for the period: 468.9 n nQuarter ended 31.03.2024 nTotal Revenue from Operations: 4970.4 nTotal expenses: 3998.8 nProfit before tax: 971.6 nTotal tax expense: 339.6 nNet profit for the period: 632.0 n nYear ended 31.03.2025 nTotal Revenue from Operations: 18974.9 nTotal expenses: 16036.4 nProfit before tax: 2938.5 nTotal tax expense: 1026.8 nNet profit for the year: 1911.7 n nYear ended 31.03.2024 nTotal Revenue from Operations: 17838.7 nTotal expenses: 14969.7 nProfit before tax: 2869.0 nTotal tax expense: 1002.6 nNet profit for the year: 1866.4 n n4. The comparative financial information of the Company for the quarter and year ended 31 March 2024 prepared in accordance with Ind AS included in this statement have been reviewed and audited respectively by the predecessor auditor. The report of the predecessor auditor on the comparative financial information is dated 29 May 2024. These previously issued financial information have been adjusted to comply with Ind AS 105 Non-current Assets Held for Sale and Discontinued Operations and included in this Statement as comparative financial information. The adjustments made to the previously issued financial information to comply with Ind AS have been reviewed and audited by existing auditors as applicable. n n5. Exceptional items for the year ended 31 March 2024 includes impairment loss of INR 415.6 Million towards its plant located at Indore and net loss on account of a cyber security incident at one of the subsidiaries amounting to INR 222.7 Million. n nExceptional items for the quarter ended 31 March 2024 includes an impairment loss of INR 415.6 Million towards its plant located at Indore and recovery of loss on cyber security incident amounting to INR 290.4 Million. n n6. During the year the Company as a part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale. n n7. The Board of Directors at its meeting held on 29 May 2025 have declared a final dividend of INR 8 per equity share face value of INR 2 each in addition to the interim dividend INR 37 per equity share face value of INR 2 each declared on 07 February 2025. The final dividend is subject to approval at the ensuing annual general meeting of the Company. n n8. The Company operates in one reportable business segment i.e. Pharmaceuticals accordingly no separate disclosure of segment information has been made.



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 In respect of continuing operations: -50800000 -170300000
2 In respect of discontinued operations: -11200000 -6500000
Total Amount of items that will not be reclassified to profit and loss -62000000 -176800000
2 Income tax relating to items that will not be reclassified to profit or loss -21700000 -61800000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -40300000 -115000000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 23035400000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 780800000
Adjustments for decrease (increase) in inventories -203800000
Adjustments for decrease (increase) in trade receivables, current -2379100000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 790900000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 2014800000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 2894200000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 137300000
Adjustments for provisions, current 177100000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -179600000
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) -400300000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 2860000000
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 6492300000
Net cash flows from (used in) operations 29527700000
Dividends received -661900000
Interest paid 0
Interest received -2978200000
Income taxes paid (refund) 3966300000
Other inflows (outflows) of cash -27200000
Net cash flows from (used in) operating activities 21894100000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 402600000
Purchase of property, plant and equipment 2262000000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 39499000000
Purchase of other long-term assets 51299700000
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 661900000
Interest received 2896900000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 27200000
Net cash flows from (used in) investing activities -10074100000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 4693800000
Payments of lease liabilities 88600000
Dividends paid 5021700000
Interest paid 564800000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -10368900000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1451100000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 1451100000
Cash and cash equivalents cash flow statement at beginning of period -1330700000
Cash and cash equivalents cash flow statement at end of period 120400000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins and Sells LLP Yes 31-Jul-2027


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 S and B Pharma LLC The Pharma Network LLC Subsidiary Sale of goods or services Not Applicable 2870000 147950000 356260000
2 The Pharma Network LLC S and B Pharma LLC Subsidiary Any other transaction Reimbursement of expenses to counterparty Not Applicable 11500000 474550000 484050000
3 The Pharma Network LLC Amit Ghare Key Management Personnel Any other transaction Loan repaid Not Applicable 41790000 43770000 0
4 The Pharma Network LLC Amit Ghare Key Management Personnel Remuneration Not Applicable 43520000 0 0
5 Pharmacor Pty Limited Andrew Guy Phillips Key Management Personnel Remuneration Not Applicable 11420000 0 0
6 Pharmacor Pty Limited Ashish Mallela Key Management Personnel Remuneration Not Applicable 7130000 0 0
7 The Pharma Network LLC Hindy Schiff Key Management Personnel Remuneration Not Applicable 14610000 0 0
8 The Pharma Network LLC James Gregory Giuliano Key Management Personnel Remuneration Not Applicable 17710000 0 0
9 The Pharma Network LLC John Dillaway Key Management Personnel Remuneration Not Applicable 27420000 0 0
10 Enzene Biosciences Limited Mr Himanshu Gadgil Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 15580000 0 0
11 Ascend Laboratories S.A. DE C.V Mr Pankaj Sawant Key Management Personnel Remuneration Not applicable 2620000 0 0
12 Ascend Laboratories SAS Mr Pankaj Sawant Key Management Personnel Remuneration Not applicable 0 0 0
13 Ascend Laboratories SpA Mr Rahul Bhat Key Management Personnel Remuneration Not applicable 0 0 0
14 Cachet Pharmaceuticals Private Limited Mr Sanjay Kumar Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 5420000 0 0
15 Pharmacor Pty Limited Alkem Laboratories Corporation Fellow Subsidiary Company Any other transaction Security Deposit Repaid Not Applicable 29390000 29390000 0
16 Pharmacor Pty Limited Alkem Laboratories Corporation Fellow Subsidiary Company Any other transaction Reimbursement of expenses to counterparty Not Applicable 2610000 30000 1440000
17 Pharmacor Pty Limited Pharmacor Limited Subsidiary Any other transaction Reimbursement Not Applicable 340000 5140000 5100000
18 Enzene Biosciences Limited Mr Viral Shah Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 3290000 0 0
19 Ascend Laboratories SpA Mr Rahul Bhat Key Management Personnel Any other transaction Reimbursement of expenses to counterparty Not applicable 0 0 0
20 The PharmaNetwork LLP Mr Viralkumar Girishkumar Parikh Key Management Personnel Remuneration Not applicable 11270000 0 0
21 Ascend Laboratories S.A. DE C.V Mr Pankaj Sawant Key Management Personnel Any other transaction Reimbursement of expenses to counterparty Not applicable 300000 0 0
22 Indchemie Health Specialities Private Limited Mr. Abhay Kumar Sinha Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 7120000 0 0
23 Ascend Laboratories SAS Mr Pankaj Sawant Key Management Personnel Any other transaction Loan repaid Not applicable 330000 210000 0
24 Indchemie Health Specialities Private Limited Mr. Anand Ramaswamy Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 7380000 0 0
25 Alkem Laboratories Limited Mr. Aniruddha Singh Relative of Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 2610000 0 0
26 Alkem Laboratories Limited Mr. Basudeo Narain Singh Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 130640000 0 0
27 Pharmacor Limited Nikhilesh Shrivastava Key Management Personnel Any other transaction Reimbursement of expenses to counterparty Not applicable 50000 930000 0
28 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Purchase of goods or services 4000000000 Approved by the audit committee of the entity 802900000 246060000 181950000
29 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Services received 500000000 Approved by the audit committee of the entity 29850000 246060000 181950000
30 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Royalty expenses 100000000 Approved by the audit committee of the entity 90000 246060000 181950000
31 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Rent Income 50000000 Approved by the audit committee of the entity 2840000 0 0
32 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Sale of goods or services 200000000 Approved by the audit committee of the entity 5470000 47740000 31570000
33 Alkem Laboratories Limited Alkem Laboratories Korea Inc. Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 60000 2080000 2180000
34 Alkem Laboratories Limited Ascend GmbH Subsidiary Sale of goods or services 1700000000 Approved by the audit committee of the entity 1033110000 387660000 826730000
35 Alkem Laboratories Limited Ascend GmbH Subsidiary Any other transaction Reimbursement of expenses to counterparty 100000000 Approved by the audit committee of the entity 47840000 0 59240000
36 Alkem Laboratories Limited Ascend Laboratories Pty Ltd Subsidiary Sale of goods or services 300000000 Approved by the audit committee of the entity 61580000 73270000 97700000
37 Alkem Laboratories Limited Ascend Laboratories UK Limited Subsidiary Sale of goods or services 1300000000 Approved by the audit committee of the entity 338080000 556780000 504220000
38 Alkem Laboratories Limited Ascend Laboratories UK Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty 150000000 Approved by the audit committee of the entity 45670000 0 57940000
39 Ascend Laboratories UK Limited Mr Alok Verma Subsidiary Remuneration Not Applicable 380000 0 0
40 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Step down subsidiary Any other transaction Reimbursement of expenses to counterparty 50000000 Approved by the audit committee of the entity 5420000 6270000 11810000
41 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Sale of goods or services 300000000 Approved by the audit committee of the entity 104330000 176300000 170180000
42 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Reimbursement of expenses to counterparty 100000000 Approved by the audit committee of the entity 1870000 1650000 1890000
43 Alkem Laboratories Limited Ascend Laboratories SDN BHD. Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 40000 1520000 1590000
44 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 1490000 0 0
45 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Any other transaction Loan Given Approved by the audit committee of the entity 84790000 0 86280000 Loan 0.057 5 Unsecured Working capital
46 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Sale of goods or services 3000000000 Approved by the audit committee of the entity 999410000 922730000 748770000
47 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Guarantee commission Not Applicable 2590000 922730000 748770000
48 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Services rendered 200000000 Approved by the audit committee of the entity 12660000 922730000 748770000
49 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Step down subsidiary Sale of goods or services 400000000 Approved by the audit committee of the entity 250000 18100000 18720000
50 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Reimbursement of Expenses by us 50000000 Approved by the audit committee of the entity 14350000 0 748770000
51 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Reimbursement of Expenses by party 50000000 Approved by the audit committee of the entity 9020000 780000 16930000
52 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Sale of goods or services 26000000000 Approved by the audit committee of the entity 8159260000 6038110000 7479410000
53 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Royalty income 200000000 Approved by the audit committee of the entity 47220000 6038110000 7479410000
54 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Services rendered 500000000 Approved by the audit committee of the entity 52830000 6038110000 7479410000
55 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Reimbursement of expenses to counterparty 1400000000 Approved by the audit committee of the entity 273870000 1188970000 931550000
56 Alkem Laboratories Limited Pharma Network SpA Step down subsidiary Any other transaction Guarantee commission Not Applicable 990000 0 1320000
57 Alkem Laboratories Limited Pharma Network SpA Step down subsidiary Any other transaction Reimbursement of Expenses by party 10000000 Approved by the audit committee of the entity 1680000 1800000 1320000
58 Alkem Laboratories Limited Pharmacor Limited Subsidiary Sale of goods or services 300000000 Approved by the audit committee of the entity 53370000 108880000 91560000
59 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Sale of goods or services 2600000000 Approved by the audit committee of the entity 1134870000 996380000 1089310000
60 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Guarantee commission Not Applicable 390000 996380000 1089310000
61 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty 550000000 Approved by the audit committee of the entity 74700000 536020000 219160000
62 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Services rendered 200000000 Approved by the audit committee of the entity 2810000 996380000 1089310000
63 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Reimbursement of Expenses by party 500000000 Approved by the audit committee of the entity 143160000 996380000 1089310000
64 Alkem Laboratories Limited S&B Pharma LLC Step down subsidiary Sale of goods or services 150000000 Approved by the audit committee of the entity 0 25900000 26420000
65 Alkem Laboratories Limited S&B Pharma LLC Step down subsidiary Purchase of goods or services 50000000 Approved by the audit committee of the entity 0 76380000 70420000
66 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Sale of goods or services 1820000000 Approved by the audit committee of the entity -128120000 925880000 698040000
67 Alkem Laboratories Limited Ms. Divya Singh Relatives of Key Managerial Personnel Any other transaction Consultancy fees 10000000 Approved by the audit committee of the entity 1500000 0 0
68 Alkem Laboratories Limited Mr. Rajeev Kher Key Management Personnel Any other transaction Commission As per approval of Board of Directors or Shareholders of the entity as necessary 1300000 0 0
69 Alkem Laboratories Limited Mrs. Madhurima Singh Key Management Personnel Any other transaction Rent expenses 50000000 Approved by the audit committee of the entity 990000 0 0
70 Alkem Laboratories Limited Mr. Sarvesh Singh Key Management Personnel Any other transaction Rent expenses 50000000 Approved by the audit committee of the entity 520000 0 0
71 Alkem Laboratories Limited Ms. Divya Singh Relatives of Key Managerial Personnel Any other transaction Rent expenses 50000000 Approved by the audit committee of the entity 570000 0 0
72 Alkem Medtech Private Limited Mr. Kaustav Banerjee Subsidiary Remuneration As per approval of Board of Directors or Shareholders of the entity as necessary 15690000 0 0
73 S&B Pharma LLC Mr. Les Ordway Key Management Personnel Remuneration Not Applicable 11450000 0 0
74 Alkem Laboratories Limited Mr. Manish Narang Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 12270000 0 0
75 Alkem Laboratories Limited Mr. Mritunjay Kumar Singh Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 74260000 0 0
76 Alkem Laboratories Limited Mr. Nitin Agrawal Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 21360000 0 0
77 Alkem Laboratories Limited Mr. A.K.Purwar Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 2200000 0 0
78 Alkem Laboratories Limited Ms. Sangeeta Singh Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 1700000 0 0
79 Alkem Laboratories Limited Ms. Sudha Ravi Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 1750000 0 0
80 Alkem Laboratories Limited Mr. Dheeraj Sharma Key Management Personnel Any other transaction Commission As per approval of Board of Directors or Shareholders of the entity as necessary 0 0 0
81 Alkem Laboratories Limited Mr. Narendra Kumar Aneja Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 1750000 0 0
82 Alkem Laboratories Limited Mr. Sandeep Singh Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 31890000 0 0
83 Alkem Laboratories Limited Mr. Sarandhar Singh Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 40660000 0 0
84 Alkem Laboratories Limited Mr. Sarvesh Singh Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 26810000 0 0
85 Alkem Laboratories Limited Mr. Satish Kumar Singh Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 39570000 0 0
86 Alkem Laboratories Limited Mr. Sujjain Talwar Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 1550000 0 0
87 Alkem Laboratories Limited Mr. Srinivas Singh Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 60840000 0 0
88 Alkem Laboratories Limited Mr. Sarvesh Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 2920000 0 0
89 Alkem Laboratories Limited Mr. Sandeep Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 6670000 0 0
90 Alkem Laboratories Limited Mr. Sarandhar Singh Relatives of Key Managerial Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 630000 0 0
91 Alkem Laboratories Limited Mr. Basudeo Narain Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 63000000 0 0
92 Alkem Laboratories Limited Mr. Srinivas Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 15930000 0 0
93 Alkem Laboratories Limited Mr. Manish Narang Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 0 0 0
94 Ascend Laboratories SpA Pharma Network SpA Subsidiary Sale of goods or services Not Applicable 358030000 291850000 204720000
95 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Purchase of goods or services 1500000000 Approved by the audit committee of the entity 243770000 180100000 130120000
96 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Sale of goods or services 100000000 Approved by the audit committee of the entity 1170000 180100000 130120000
97 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Services received 900000000 Approved by the audit committee of the entity 210410000 180100000 130120000
98 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Rent Income 30000000 Approved by the audit committee of the entity 10700000 180100000 130120000
99 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Purchase of goods or services 3000000000 Approved by the audit committee of the entity 847190000 255100000 0
100 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Royalty income 200000000 Approved by the audit committee of the entity 29810000 77330000 0
101 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Guarantee commission Not Applicable 11900000 77330000 0
102 Alkem Laboratories Limited Galpha Laboratories Limited Affiliate Purchase of goods or services 200000000 Approved by the audit committee of the entity 65980000 78410000 15910000
103 Alkem Laboratories Limited Galpha Laboratories Limited Affiliate Any other transaction Rent Income 50000000 Approved by the audit committee of the entity 1900000 0 0
104 Alkem Laboratories Limited Connect 2 Clinic Private Limited Subsidiary Any other transaction Services received 200000000 Approved by the audit committee of the entity 60020000 23070000 25310000
105 Alkem Laboratories Limited Alkem Foundation Subsidiary Any other transaction Donations given 600000000 Approved by the audit committee of the entity 104400000 0 0
106 Indchemie Health Specialities Private Limited Cachet Pharmaceuticals Private Limited Fellow Subsidiary Company Sale of goods or services Approved by the audit committee of the entity 38880000 0 0
107 Indchemie Health Specialities Private Limited Cachet Pharmaceuticals Private Limited Fellow Subsidiary Company Any other transaction Reimbursement of Expenses by party Not Applicable 80000 11350000 4880000
108 Alkem Laboratories Limited Mr. Vikas Gupta Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 75720000 0 0
109 Alkem Laboratories Limited Mrs. Madhurima Singh Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 60130000 0 0
110 Indchemie Health Specialities Private Limited Mr. Mritunjay Kumar Singh Key Management Personnel Any other transaction Rent expenses Not Applicable 120000 0 0
111 Cachet Pharmaceuticals Private Limited Galpha Laboratories Limited Affiliate Purchase of goods or services Approved by the audit committee of the entity 5690000 4610000 3680000
112 Enzene Biosciences Limited Enzene Inc Subsidiary Investment As per approval of Board of Directors Shareholders NRC of the entity as necessary 192590000 1901320000 2093920000 Investment 0 0 Unsecured Business Requirements
113 Enzene Biosciences Limited Enzene Inc Subsidiary Loan As per approval of Board of Directors Shareholders NRC of the entity as necessary 1904040000 0 1904040000 Loan 0 7 Unsecured Business Requirements Textual Information(1)
114 Enzene Biosciences Limited Enzene Inc Subsidiary Any other transaction Reimbursement of expenses to counterparty Not Applicable 1250000 10990000 0
115 Enzene Biosciences Limited Ms Shilpa Gadgil Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 4720000 0 0
116 Enzene Biosciences Limited Mr Neel Ambani Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 3150000 0 0
117 Enzene Biosciences Limited Ms Yogita Hanamshet Key Management Personnel Remuneration As per approval of Board of Directors Shareholders NRC of the entity as necessary 1080000 0 0
118 Pharmacor Limited Nikhilesh Shrivastava Key Management Personnel Remuneration Not applicable 15310000 0 0
119 Pharmacor Pty Limited Richard Mlynarick Key Management Personnel Remuneration Not Applicable 4210000 0 0
120 Cachet Pharmaceuticals Private Limited Mr. Arunkumar Deshmukh Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 40000 0 0
121 The Pharma Network LLC Mr. Sandeep Singh Key Management Personnel Remuneration As per approval of Board of Directors. 40490000 0 0
122 Cachet Pharmaceuticals Private Limited Dr. Anuja Sinha Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0 0 0
123 Indchemie Health Specialities Private Limited Mr Akhouri Maheshwari Prasad Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 180000 0 0
124 Indchemie Health Specialities Private Limited Mr Gautam Gulabchand Parekh Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 180000 0 0
125 Enzene Biosciences Limited Ms. Sangeeta Singh Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 180000 0 0
126 Enzene Biosciences Limited Ms. Sudha Ravi Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 180000 0 0
127 Alkem Laboratories Limited Ascend Laboratories LLC Subsidiary Any other transaction Guarantee commission Not Applicable 6400000 0 0
128 Ascend GmbH Enzene Biosciences Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty Not Applicable 0 20970000 20100000
129 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Sale of goods or services 200000000 Approved by the audit committee of the entity 0 0 0
130 Pharmacor Pty Limited The Pharma Network LLC Fellow Subsidiary Company Purchase of goods or services Not Applicable 30000 0 0
131 The Pharma Network LLC Schuyler Van Winkle Key Management Personnel Remuneration Not Applicable 22910000 0 0
132 Ascend GmbH Vikas Singh Key Management Personnel Remuneration Not applicable 11970000 0 0
133 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Investment As per approval of Board of Directors Shareholders NRC of the entity as necessary 2500000000 0 0 Investment 0 0 Unsecured Business Requirements
134 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of Expenses by party 250000000 Approved by the audit committee of the entity 10990000 2000000 230000
135 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of expenses by us 10000000 Approved by the audit committee of the entity 230000 0 230000
136 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Investment As per approval of Board of Directors Shareholders NRC of the entity as necessary 0 0 2000000
137 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty 50000000 Approved by the audit committee of the entity 9750000 0 9750000
138 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Investment As per approval of Board of Directors Shareholders NRC of the entity as necessary 50000000 0 50000000 Investment 0 0 Unsecured Business Requirements
139 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty 100000000 Approved by the audit committee of the entity 30260000 0 30280000
140 The Pharma Network LLC William Moran Key Management Personnel Remuneration Not Applicable 9050000 0 0
141 Ascend Laboratories SpA Carlos Mora Key Management Personnel Remuneration Not Applicable 12610000 0 0
142 Ascend Laboratories SpA Carlos Mora Key Management Personnel Any other transaction Reimbursement of expenses to counterparty Not Applicable 4020000 0 0
143 Ascend Laboratories SpA Mauricio Torra Key Management Personnel Remuneration Not Applicable 7470000 0 0
144 Ascend Laboratories SpA Mauricio Torra Key Management Personnel Any other transaction Reimbursement of expenses to counterparty Not Applicable 450000 0 0
145 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Dividend Received from subsidiary Not Applicable 636000000 0 0
146 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Dividend Received from subsidiary Not Applicable 25500000 0 0
147 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty Not Applicable 4260000 0 0
148 Alkem Laboratories Limited Connect 2 Clinic Private Limited Subsidiary Any other transaction Reimbursement of expenses to counterparty Not Applicable 770000 0 0
149 Alkem Laboratories Limited Pharmacor SPA Subsidiary Any other transaction Guarantee commission Not Applicable 120000 0 0
150 Alkem Laboratories Limited Haystack Analytics Pvt Ltd Associate Investment As per approval of Board of Directors Shareholders NRC of the entity as necessary 30000000 300000000 330000000 Investment 0 0 Unsecured Business Requirements Textual Information(2)
Total value of transaction during the reporting period 21922110000



Text Block
Textual Information(1) Interest Rate - 3 Months TSOFR + 475 bps
Textual Information(2) Investment converted to Associate in H2